Tacrolimus in rheumatoid arthritis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 1, 2006, Pages 91-98

  Fleischmann, Roy ^a,b   Iqbal, Imran ^c   Stern, Richard L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b RADIANT RESEARCH   (United States)

^c St Paul University Hospital   (United States)

Author keywords

Disease modifying anti rheumatic drugs; Rheumatoid arthritis; Tacrolimus

Indexed keywords

CALCINEURIN; CHLORAMPHENICOL; CIMETIDINE; CLARITHROMYCIN; CLOTRIMAZOLE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOKINE; DILTIAZEM; ERYTHROMYCIN; FK 506 BINDING PROTEIN; GAMMA INTERFERON; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; ITRACONAZOLE; KETOCONAZOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; NIFEDIPINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ATOPIC DERMATITIS; CARTILAGE DEGENERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPEPSIA; FLU LIKE SYNDROME; FUNCTIONAL STATUS; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER GRAFT REJECTION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREATITIS; PNEUMONIA; RESPIRATORY FAILURE; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; STREPTOMYCES TSUKUBAENSIS; T LYMPHOCYTE ACTIVATION; TREMOR; URINARY TRACT INFECTION;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; TACROLIMUS;

EID: 30344479898     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.1.91     Document Type: Review

References (41)

1. O'DELL JR: Rheumatoid arthritis: the clinical picture. In: Arthritis and Allied Conditions. WJ Koopman (Ed). Lippincott Williams & Wilkins, Philadelphia, USA (2001):1153-1186.
2. CHEHATA JC, HASSELL AB, CLARKE SA et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (2001) 40(4):447-452.
3. GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. (2003) 48(1):54-58.
4. YOUNG A, DIXEY J, KULINSKAYA E et al.: Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis. (2002) 61(4):335-340.
5. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344(12):907-916.
6. VAN RIJTHOVEN AW, DIJKMANS BA, THE HS et al.: Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. J. Rheumatol. (1991) 18(6):815-820.
7. WELLS G, HAGUENAUER D, SHEA B et al.: Cyclosporine for rheumatoid arthritis. Cochrane. Database. Syst. Rev. (2000) 2:CD001083.
8. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. (1995) 333(3):137-141.
9. SAVADA S, SUZUKI G. KAWASE Y, TAKAKU F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. (1987) 139(6):1797-1803.
10. FLEISCHMANN R: Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert. Opin. Drug Saf. (2003) 2(4):347-365.
11. FLEISCHMANN RM, IQBAL I, STERN RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert. Opin. Drug Saf. (2004) 3(5):391-403.
12. STAATZ CE, TETT SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. (2004) 43(10):623-653.
13. Fujisawa Healthcare, Inc.: Prograf® (tacrolimus) prescribing information. Deerfield, IL, USA (2005).
14. MIYATA S, OHKUBO Y, MUTOH S: A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm. Res. (2005) 54(1):1-9.
15. TOCCI MJ, MATKOVICH DA, COLLIER KA et al.: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. (1989) 143(2):718-726.
16. SAWADA S, SUZUKI G, KAWASE Y, TAKAKU F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. (1987) 139(6):1797-1803.
17. SUGIYAMA E, SUZUKI H, TUNRU IS et al.: FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. J. Rheumatol. (1994) 21(9):1597-1601.
18. SAKUMA S, KATO Y, NISHIGAKI F et al.: FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br. J. Pharmacol. (2000) 130(7):1655-1663.
19. FUSELER JW, HEARTH-HOLMES M, GRISHAM MB et al.: FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis. J. Rheumatol. (2000) 27(1):190-199.
20. MAGARI K, NISHIGAKI F, SASAKAWA T et al.: Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm. Res. (2003) 52(12):524-529.
21. SAKUMA S, NISHIGAKI F, MAGARI K et al.: FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm. Res. (2001) 50(10):509-514.
22. MAGARI K, MIYATA S, NISHIGAKI F, OHKUBO Y, MUTOH S: Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm. Res. (2004) 53(10):544-550.
23. MAGARI K, MIYATA S, OHKUBO Y, MUTOH S, GOTO T: Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br. J. Pharmacol. (2003) 139(5):927-934.
24. WALLEMACQ PE, VERBEECK RK: Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin. Pharmacokinet. (2001) 40(4):283-295.
25. HOLUM MB, WISEMANDLE W, BEKERSKY I: Concomitant tacrolimus (TAC) and methotrexate(MTX) pharmacokinetics (PK) in rheumatoid arthritis (RA) patients. J. Clin. Pharmacol. (2002) 42:1053.
26. GREMILLION RB, POSEVER JO, MANEK N, WEST JP, VAN VOLEN-HOVEN RF: Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J. Rheumatol. (1999) 26(11):2332-2336.
27. FURST DE, SAAG K, FLEISCHMANN MR et al.: Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. (2002) 46(8):2020-2028.
28. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology, Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38(6):727-735.
29. KONDO H, ABE T, HASHIMOTO H et al.: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J. Rheumatol. (2004) 31(2):243-251.
30. YOCUM DE, FURST DE, KAINE JL et al.: Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. (2003) 48(12):3328-3337.
31. PARKER CT, RENNIE T: Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. Arthritis Rheum. (2004) 50(9):3051-3052.
32. KREMER JM, HABROS JS, KOLBA KS et al.: Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. (2003) 48(10):2763-2768.
33. YOCUM DE, FURST DE, BENSEN WG et al.: Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (2004) 43(8):992-999.
34. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. (1999) 159(21):2542-2550.
35. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130(6):478-486.
36. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. (1993) 36(12):1681-1690.
37. VAN DE PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. (2004) 63(5):508-516.
38. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2002) 137(9):726-733.
39. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340(4):253-259.
40. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354(9194):1932-1939.
41. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50(5):1400-1411.